Develops specialized valves for fluid and gas control in medical applications. Manufactures the Myocardial Protection System for cardiovascular procedures. Now — the numbers.
The biggest line carries real weight, but it doesn’t decide everything on its own.
This is an established company with proven profits.
No real growth (2% a year).
If every debt were paid off today, $6.0M would still be left — though next to the size of the company that is a thin cushion.
The market pays 41.7× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
There is $6.3M in the vault; even if every debt were paid off, $6.0M would remain.
It pays out $8.80 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
The company’s market value is 42 times its annual profit. Even a small disappointment could hit the price hard.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution.